Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma

There are limited and no standard therapies for recurrent glioblastoma. We herein report the antitumour activity and safety of sintilimab, bevacizumab and temozolomide (TMZ) in recurrent glioblastoma.